GlassScriptPhysician profile
Jeffrey C Silverstein
NPI 1861580680
$3,394.77
in general payments reported to CMS, 2019-2025
22 companies · $374 in 2025
The $374 reported for 2025 was more than what 88% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $217 · 2021: $518 · 2022: $773 · 2023: $654 · 2024: $531 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $678.99 | 2019-2024 | |
| Tris Pharma INC | $386.66 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $367.28 | 2022-2025 | Azstarys |
| Baxter Healthcare | $350.73 | 2022 | |
| Alk-Abello, INC | $306.26 | 2023-2025 | Odactra, Grastek, Ragwitek |
| Kaleo, INC. | $264.66 | 2019-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $260.60 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Sanofi Pasteur INC. | $106.25 | 2023-2025 | |
| Cranial Technologies, INC | $94.50 | 2021-2025 | Doc Band |
| Kestra Medical Technology Services, INC. | $84.41 | 2023 | Assure Wcd |
| Stryker Corporation | $73.81 | 2024 | Mako |
| Supernus Pharmaceuticals, INC. | $73.38 | 2021-2024 | Qelbree |
| Collegium Pharmaceutical, INC. | $70.11 | 2025 | Jornay Pm |
| Aytu Biopharma, INC. | $56.99 | 2022-2023 | |
| Cumberland Pharmaceuticals, INC. | $47.66 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.91 | 2019-2022 | |
| Glaxosmithkline, LLC. | $39.33 | 2019-2025 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $19.64 | 2021 | |
| Boston Scientific Corporation | $19.64 | 2025 | General - Therapies |
| Seqirus USA INC | $17.92 | 2022 | |
| Shionogi INC | $16.62 | 2023 | Fetroja |
| Phadia US INC. | $15.42 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Silverstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.